Cargando…

Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()

Macrophages are important inflammatory cells that regulate innate and adaptive immunity in cancer. Tumor-associated macrophages (TAMs) are thought to differentiate into two main phenotypes: proinflammatory M1 and protumorigenic M2. Currently, the prognostic impact of TAMs and their M1 and M2 phenoty...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakaee, Mehrdad, Busund, Lill-Tove Rasmussen, Jamaly, Simin, Paulsen, Erna-Elise, Richardsen, Elin, Andersen, Sigve, Al-Saad, Samer, Bremnes, Roy M., Donnem, Tom, Kilvaer, Thomas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369140/
https://www.ncbi.nlm.nih.gov/pubmed/30743162
http://dx.doi.org/10.1016/j.neo.2019.01.005
_version_ 1783394119322697728
author Rakaee, Mehrdad
Busund, Lill-Tove Rasmussen
Jamaly, Simin
Paulsen, Erna-Elise
Richardsen, Elin
Andersen, Sigve
Al-Saad, Samer
Bremnes, Roy M.
Donnem, Tom
Kilvaer, Thomas K.
author_facet Rakaee, Mehrdad
Busund, Lill-Tove Rasmussen
Jamaly, Simin
Paulsen, Erna-Elise
Richardsen, Elin
Andersen, Sigve
Al-Saad, Samer
Bremnes, Roy M.
Donnem, Tom
Kilvaer, Thomas K.
author_sort Rakaee, Mehrdad
collection PubMed
description Macrophages are important inflammatory cells that regulate innate and adaptive immunity in cancer. Tumor-associated macrophages (TAMs) are thought to differentiate into two main phenotypes: proinflammatory M1 and protumorigenic M2. Currently, the prognostic impact of TAMs and their M1 and M2 phenotypes is unclear in non–small cell cancer (NSCLC). The present study was set up to evaluate an approach for identifying common M1 and M2 macrophage markers and explore their clinical significance in NSCLC. Using multiplex chromogenic immunohistochemistry, tissue microarrays of 553 primary tumors and 143 paired metastatic lymph nodes of NSCLC specimens were stained to detect various putative macrophage phenotypes: M1 (HLA-DR/CD68), M2 (CD163/CD68), M2 (CD204/CD68), and pan-macrophage (CD68/CK). Correlation analyses were performed to examine the relationship between TAMs and adaptive/innate immune infiltrates. HLA-DR(+)/CD68(+)M1 TAM level significantly decreased from pathological stage I to III. In a compartment-specific correlation analysis, moderate to strong correlations were observed between both TAM subsets (M1 and M2) with CD3-, CD8-, CD4-, and CD45RO-positive immune cells. Survival analyses, in both stromal and intratumoral compartments, revealed that high levels of HLA-DR(+)/CD68(+)M1 (stroma, hazard ratio [HR] = 0.73, P = .03; intratumor, HR = 0.7, P = .04), CD204(+)M2 (stroma, HR = 0.7, P = .02; intratumor, HR = 0.6, P = .004), and CD68 (stroma, HR = 0.69, P = .02; intratumor, HR = 0.73, P = .04) infiltration were independently associated with improved NSCLC-specific survival. In lymph nodes, the intratumoral level of HLA-DR(+)/CD68(+)M1 was an independent positive prognostic indicator (Cox model, HR = 0.38, P = .001). In conclusion, high levels of M1, CD204(+)M2, and CD68 macrophages are independent prognosticators of prolonged survival in NSCLC.
format Online
Article
Text
id pubmed-6369140
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-63691402019-02-20 Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry() Rakaee, Mehrdad Busund, Lill-Tove Rasmussen Jamaly, Simin Paulsen, Erna-Elise Richardsen, Elin Andersen, Sigve Al-Saad, Samer Bremnes, Roy M. Donnem, Tom Kilvaer, Thomas K. Neoplasia Original article Macrophages are important inflammatory cells that regulate innate and adaptive immunity in cancer. Tumor-associated macrophages (TAMs) are thought to differentiate into two main phenotypes: proinflammatory M1 and protumorigenic M2. Currently, the prognostic impact of TAMs and their M1 and M2 phenotypes is unclear in non–small cell cancer (NSCLC). The present study was set up to evaluate an approach for identifying common M1 and M2 macrophage markers and explore their clinical significance in NSCLC. Using multiplex chromogenic immunohistochemistry, tissue microarrays of 553 primary tumors and 143 paired metastatic lymph nodes of NSCLC specimens were stained to detect various putative macrophage phenotypes: M1 (HLA-DR/CD68), M2 (CD163/CD68), M2 (CD204/CD68), and pan-macrophage (CD68/CK). Correlation analyses were performed to examine the relationship between TAMs and adaptive/innate immune infiltrates. HLA-DR(+)/CD68(+)M1 TAM level significantly decreased from pathological stage I to III. In a compartment-specific correlation analysis, moderate to strong correlations were observed between both TAM subsets (M1 and M2) with CD3-, CD8-, CD4-, and CD45RO-positive immune cells. Survival analyses, in both stromal and intratumoral compartments, revealed that high levels of HLA-DR(+)/CD68(+)M1 (stroma, hazard ratio [HR] = 0.73, P = .03; intratumor, HR = 0.7, P = .04), CD204(+)M2 (stroma, HR = 0.7, P = .02; intratumor, HR = 0.6, P = .004), and CD68 (stroma, HR = 0.69, P = .02; intratumor, HR = 0.73, P = .04) infiltration were independently associated with improved NSCLC-specific survival. In lymph nodes, the intratumoral level of HLA-DR(+)/CD68(+)M1 was an independent positive prognostic indicator (Cox model, HR = 0.38, P = .001). In conclusion, high levels of M1, CD204(+)M2, and CD68 macrophages are independent prognosticators of prolonged survival in NSCLC. Neoplasia Press 2019-02-10 /pmc/articles/PMC6369140/ /pubmed/30743162 http://dx.doi.org/10.1016/j.neo.2019.01.005 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Rakaee, Mehrdad
Busund, Lill-Tove Rasmussen
Jamaly, Simin
Paulsen, Erna-Elise
Richardsen, Elin
Andersen, Sigve
Al-Saad, Samer
Bremnes, Roy M.
Donnem, Tom
Kilvaer, Thomas K.
Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
title Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
title_full Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
title_fullStr Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
title_full_unstemmed Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
title_short Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry()
title_sort prognostic value of macrophage phenotypes in resectable non–small cell lung cancer assessed by multiplex immunohistochemistry()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369140/
https://www.ncbi.nlm.nih.gov/pubmed/30743162
http://dx.doi.org/10.1016/j.neo.2019.01.005
work_keys_str_mv AT rakaeemehrdad prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT busundlilltoverasmussen prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT jamalysimin prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT paulsenernaelise prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT richardsenelin prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT andersensigve prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT alsaadsamer prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT bremnesroym prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT donnemtom prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry
AT kilvaerthomask prognosticvalueofmacrophagephenotypesinresectablenonsmallcelllungcancerassessedbymultipleximmunohistochemistry